{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:45:45Z","timestamp":1782978345265,"version":"3.54.5"},"reference-count":158,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:00:00Z","timestamp":1582588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00337","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T06:19:43Z","timestamp":1582611583000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":39,"title":["Immunotherapies in Huntington's disease and \u03b1-Synucleinopathies"],"prefix":"10.3389","volume":"11","author":[{"given":"Oluwaseun","family":"Fatoba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Ohtake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahide","family":"Itokazu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihide","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1146\/annurev.ge.29.120195.003415","article-title":"Trinucleotide repeat expansion and human disease","volume":"29","author":"Ashley","year":"1995","journal-title":"Annu Rev Genet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1042\/bst0260471","article-title":"Polyglutamine expansion and Huntington's disease","volume":"26","author":"Bates","year":"1998","journal-title":"Biochem Soc Trans."},{"key":"B3","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1093\/hmg\/9.6.909","article-title":"Fourteen and counting: unraveling trinucleotide repeat diseases","volume":"9","author":"Cummings","year":"2000","journal-title":"Hum Mol Genet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.pneurobio.2013.01.001","article-title":"Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7","volume":"104","author":"R\u00fcb","year":"2013","journal-title":"Prog Neurobiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell."},{"key":"B6","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington's disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington's disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3233\/JPD-140523","article-title":"Parkinson's disease subtypes in the oxford Parkinson disease centre (OPDC) discovery cohort","volume":"5","author":"Lawton","year":"2015","journal-title":"J Parkinsons Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1136\/jnnp-2018-318337","article-title":"Developing and validating Parkinson's disease subtypes and their motor and cognitive progression","volume":"89","author":"Lawton","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B10","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.3233\/JPD-179005","article-title":"The synucleinopathies: twenty years on","volume":"7","author":"Goedert","year":"2017","journal-title":"J Parkinsons Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41586-018-0104-4","article-title":"Cellular milieu imparts distinct pathological alpha-synuclein strains in alphasynucleinopathies","volume":"557","author":"Peng","year":"2018","journal-title":"Nature."},{"key":"B12","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1002\/1099-1166(200112)16:1+<::aid-gps562>3.0.co;2-3","article-title":"Dementia with Lewy bodies: diagnosis and management","volume":"16","author":"Barber","year":"2001","journal-title":"Int J Geriatr Psychiatry."},{"key":"B13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13024-019-0306-8","article-title":"Dementia with Lewy bodies: an update and outlook","volume":"14","author":"Outeiro","year":"2019","journal-title":"Mol Neurodegener."},{"key":"B14","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","article-title":"Second consensus statement on the diagnosis of multiple system atrophy","volume":"71","author":"Gilman","year":"2008","journal-title":"Neurology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.14802\/jmd.18020","article-title":"Clinical and imaging features of multiple system atrophy: challenges for an early and clinically definitive diagnosis","volume":"11","author":"Watanabe","year":"2018","journal-title":"J Mov Disord."},{"key":"B16","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nrneurol.2017.26","article-title":"Multiple system atrophy: insights into a rare and debilitating movement disorder","volume":"13","author":"Krismer","year":"2017","journal-title":"Nat Rev Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.3233\/JAD-170397","article-title":"Multiple system atrophy: an oligodendroglioneural synucleinopathy1","volume":"62","author":"Jellinger","year":"2018","journal-title":"J Alzheimers Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.nbd.2017.07.018","article-title":"Distinct alphaSynuclein strains and implications for heterogeneity among alpha-Synucleinopathies","volume":"109","author":"Peng","year":"2018","journal-title":"Neurobiol Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/jnen\/60.2.161","article-title":"Early and progressive accumulation of reactive microglia in the Huntington disease brain","volume":"60","author":"Sapp","year":"2001","journal-title":"J Neuropathol Exp Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1212\/01.wnl.0000222734.56412.17","article-title":"Microglial activation correlates with severity in Huntington disease: a clinical and PET study","volume":"66","author":"Pavese","year":"2006","journal-title":"Neurology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1084\/jem.20080178","article-title":"A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease","volume":"205","author":"Bj\u00f6rkqvist","year":"2008","journal-title":"J Exp Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nn.3668","article-title":"Mutant Huntingtin promotes autonomous microglia activation via myeloid lineagedetermining factors","volume":"17","author":"Crotti","year":"2014","journal-title":"Nat Neurosci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1172\/JCI64565","article-title":"Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression","volume":"122","author":"Weiss","year":"2012","journal-title":"J Clin Invest."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/hmg\/ddt036","article-title":"A critical role of astrocyte-mediated nuclear factor-kappaB-dependent inflammation in Huntington's disease","volume":"22","author":"Hsiao","year":"2013","journal-title":"Hum Mol Genet."},{"key":"B25","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/brain\/awt355","article-title":"HTT-lowering reverses Huntington's disease immune dysfunction caused by NFkappaB pathway dysregulation","volume":"137","author":"Tr\u00e4ger","year":"2014","journal-title":"Brain."},{"key":"B26","doi-asserted-by":"publisher","first-page":"11447","DOI":"10.1038\/s41598-018-29792-x","article-title":"In vivo neutralization of the protagonist role of macrophages during the chronic inflammatory stage of Huntington's disease","volume":"8","author":"Pido-Lopez","year":"2018","journal-title":"Sci Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/ana.20338","article-title":"Microglial activation and dopamine terminal loss in early Parkinson's disease","volume":"57","author":"Ouchi","year":"2005","journal-title":"Ann Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.nbd.2005.08.002","article-title":"In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease","volume":"21","author":"Gerhard","year":"2006","journal-title":"Neurobiol Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.bbi.2008.07.003","article-title":"Peripheral cytokines profile in Parkinson's disease","volume":"23","author":"Reale","year":"2009","journal-title":"Brain Behav Immun."},{"key":"B30","doi-asserted-by":"publisher","first-page":"9262","DOI":"10.1074\/jbc.M109.081125","article-title":"Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies","volume":"285","author":"Lee","year":"2010","journal-title":"J Biol Chem."},{"key":"B31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s40478-017-0494-9","article-title":"alpha-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration","volume":"5","author":"Harms","year":"2017","journal-title":"Acta Neuropathol Commun."},{"key":"B32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.expneurol.2017.11.010","article-title":"Peripheral monocyte entry is required for alpha-synuclein induced inflammation and neurodegeneration in a model of Parkinson disease","volume":"300","author":"Harms","year":"2018","journal-title":"Exp Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/brain\/awy265","article-title":"Early microglial activation and peripheral inflammation in dementia with Lewy bodies","volume":"141","author":"Surendranathan","year":"2018","journal-title":"Brain."},{"key":"B34","doi-asserted-by":"publisher","first-page":"946","DOI":"10.3389\/fneur.2018.00946","article-title":"The peripheral inflammatory response to alpha-synuclein and endotoxin in Parkinson's disease","volume":"9","author":"White","year":"2018","journal-title":"Front Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/ana.25557","article-title":"Increased immune activation by pathologic alpha-synuclein in Parkinson's disease","volume":"86","author":"Grozdanov","year":"2019","journal-title":"Ann Neurol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/bpa.12678","article-title":"Oligodendroglial alphasynucleinopathy-driven neuroinflammation in multiple system atrophy","volume":"29","author":"Hoffmann","year":"2019","journal-title":"Brain Pathol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1093\/brain\/awm044","article-title":"Microglial activation in presymptomatic Huntington's disease gene carriers","volume":"130","author":"Tai","year":"2007","journal-title":"Brain."},{"key":"B38","doi-asserted-by":"publisher","first-page":"541259","DOI":"10.1155\/2013\/541259","article-title":"The role of the immune system in Huntington's disease","volume":"2013","author":"Ellrichmann","year":"2013","journal-title":"Clin Dev Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"8653132","DOI":"10.1155\/2016\/8653132","article-title":"Neuroimmunology of Huntington's disease: revisiting evidence from human studies","volume":"2016","author":"Rocha","year":"2016","journal-title":"Mediators Inflamm."},{"key":"B40","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/j.1471-4159.2008.05823.x","article-title":"Induction of chemokines, MCP1, and KC in the mutant huntingtin expressing neuronal cells because of proteasomal dysfunction","volume":"108","author":"Godavarthi","year":"2009","journal-title":"J Neurochem."},{"key":"B41","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1093\/hmg\/ddx315","article-title":"IKKbeta and mutant huntingtin interactions regulate the expression of IL-34: implications for microglial-mediated neurodegeneration in HD","volume":"26","author":"Khoshnan","year":"2017","journal-title":"Hum Mol Genet."},{"key":"B42","doi-asserted-by":"publisher","first-page":"7999","DOI":"10.1523\/JNEUROSCI.2675-04.2004","article-title":"Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity","volume":"24","author":"Khoshnan","year":"2004","journal-title":"J Neurosci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.tins.2010.09.004","article-title":"alpha-Synuclein and dopamine at the crossroads of Parkinson's disease","volume":"33","author":"Venda","year":"2010","journal-title":"Trends in Neurosci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1759091418812587","DOI":"10.1177\/1759091418812587","article-title":"alpha-Synuclein trafficking in Parkinson's disease: insights from fly and mouse models","volume":"10","author":"Cheng","year":"2018","journal-title":"ASN Neuro."},{"key":"B45","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1034\/j.1600-0404.2000.101003159.x","article-title":"Impaired cytokine production by peripheral blood mononuclear cells and monocytes\/macrophages in Parkinson's disease","volume":"101","author":"Hasegawa","year":"2000","journal-title":"Acta Neurol Scand."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1016\/j.neuropharm.2012.01.028","article-title":"Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease","volume":"62","author":"Collins","year":"2012","journal-title":"Neuropharmacology."},{"key":"B47","doi-asserted-by":"publisher","first-page":"E4949","DOI":"10.1073\/pnas.1513426112","article-title":"Propagation of prions causing synucleinopathies in cultured cells","volume":"112","author":"Woerman","year":"2015","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B48","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.stemcr.2018.12.007","article-title":"Propagation of alpha-Synuclein strains within human reconstructed neuronal network","volume":"12","author":"Gribaudo","year":"2019","journal-title":"Stem Cell Rep."},{"key":"B49","doi-asserted-by":"publisher","first-page":"18675","DOI":"10.1074\/jbc.M116.734707","article-title":"The effect of fragmented pathogenic alpha-synuclein seeds on prion-like propagation","volume":"291","author":"Tarutani","year":"2016","journal-title":"J Biol Chem."},{"key":"B50","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/brain\/aww230","article-title":"Like prions: the propagation of aggregated tau and alphaSynuclein in neurodegeneration","volume":"140","author":"Goedert","year":"2017","journal-title":"Brain."},{"key":"B51","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.bbadis.2016.12.015","article-title":"Visualization of prion-like transfer in Huntington's disease models","volume":"1863","author":"Jansen","year":"2017","journal-title":"Biochim Biophys Acta Mol Basis Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"E5427","DOI":"10.1073\/pnas.1516217112","article-title":"Transcellular spreading of huntingtin aggregates in the Drosophila brain","volume":"112","author":"Babcock","year":"2015","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B53","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00401-016-1582-9","article-title":"Human-to-mouse prion-like propagation of mutant huntingtin protein","volume":"132","author":"Jeon","year":"2016","journal-title":"Acta Neuropathol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s00401-019-01973-6","article-title":"Demonstration of prion-like properties of mutant huntingtin fibrils in both in vitro and in vivo paradigms","volume":"137","author":"Masnata","year":"2019","journal-title":"Acta Neuropathol."},{"key":"B55","unstructured":"A clinical study in participants with Huntington's disease (HD) to assess efficacy and safety of three oral doses of laquinimod (LEGATO-HD)"},{"key":"B56","unstructured":"Huntington Study Group. A study in subjects with late prodromal and early manifest Huntington's disease (HD) to assess the safety, tolerability, pharmacokinetics, and efficacy of pepinemab (VX15\/2503) (SIGNAL)"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1002\/mds.23236","article-title":"A futility study of minocycline in Huntington's disease","volume":"25","year":"2010","journal-title":"Mov Disord."},{"key":"B58","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1212\/01.WNL.0000133403.30559.FF","article-title":"Minocycline safety and tolerability in Huntington disease","volume":"63","year":"2004","journal-title":"Neurology"},{"key":"B59","unstructured":"AffirisAG\n          Tolerability and Safety of Subcutaneous Administration of Two Doses of AFFITOPE\u00ae PD01A in Early Parkinson's Disease."},{"key":"B60","unstructured":"AffirisAG\n          Study Assessing Tolerability and Safety of AFFITOPE\u00ae PD03A in Patients with Early Parkinson's Disease (AFF011)"},{"key":"B61","unstructured":"AffirisAG\n          Follow-up Study to Assess a Second Boost Immunization with AFFITOPE\u00ae PD01A with Regard to Safety and Clinical Activity (AFF008AA)."},{"key":"B62","unstructured":"AffirisAG\n          Study Assessing Safety and Therapeutic Activity of AFFITOPE\u00ae PD01A and PD03A in Patients with Early MSA (AFF009)."},{"key":"B63","unstructured":"Single Ascending Dose Study of MEDI1341 in Healthy Volunteers."},{"key":"B64","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/mds.26878","article-title":"First-in-human assessment of PRX002, an anti-alpha-synuclein monoclonal antibody, in healthy volunteers","volume":"32","author":"Schenk","year":"2017","journal-title":"Mov Disord."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","article-title":"Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti-alphaSynuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial","volume":"75","author":"Jankovic","year":"2018","journal-title":"JAMA Neurol."},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27738","article-title":"Randomized phase I clinical trial of antialpha-synuclein antibody BIIB054","author":"Brys","year":"2019","journal-title":"Mov Disord."},{"key":"B67","unstructured":"A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants with Parkinson's Disease"},{"key":"B68","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41531-017-0013-5","article-title":"Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial","volume":"3","author":"Gendelman","year":"2017","journal-title":"NPJ Parkinson's disease."},{"key":"B69","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jneuroim.2004.02.016","article-title":"Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1\/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats","volume":"156","author":"Yang","year":"2004","journal-title":"J Neuroimmunol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jns.2011.02.019","article-title":"Insight into the mechanism of laquinimod action","volume":"306","author":"Br\u00fcck","year":"2011","journal-title":"J Neurol Sci."},{"key":"B71","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jneuroim.2012.06.005","article-title":"Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis","volume":"251","author":"Aharoni","year":"2012","journal-title":"J Neuroimmunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ajpath.2011.09.037","article-title":"Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor","volume":"180","author":"Thone","year":"2012","journal-title":"Am J Pathol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jneuroim.2010.02.010","article-title":"Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study","volume":"221","author":"Gurevich","year":"2010","journal-title":"J Neuroimmunol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/jnc.13553","article-title":"Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells","volume":"137","author":"Dobson","year":"2016","journal-title":"J Neurochem."},{"key":"B75","doi-asserted-by":"publisher","first-page":"31652","DOI":"10.1038\/srep31652","article-title":"Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease","volume":"6","author":"Garcia-Miralles","year":"2016","journal-title":"Sci Rep."},{"key":"B76","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.1007\/s12035-018-1393-1","article-title":"Laquinimod treatment improves myelination deficits at the transcriptional and ultrastructural levels in the YAC128 mouse model of Huntington disease","volume":"56","author":"Garcia-Miralles","year":"2019","journal-title":"Mol Neurobiol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.expneurol.2016.06.008","article-title":"Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons","volume":"283","author":"Ehrnhoefer","year":"2016","journal-title":"Exp Neurol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1038\/s41598-017-04990-1","article-title":"Laquinimod treatment in the R6\/2 mouse model","volume":"7","author":"Ellrichmann","year":"2017","journal-title":"Sci Rep."},{"key":"B79","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0092-8674(00)80063-X","article-title":"Plexins are a large family of receptors for transmembrane, secreted, and GPIanchored semaphorins in vertebrates","volume":"99","author":"Tamagnone","year":"1999","journal-title":"Cell."},{"key":"B80","doi-asserted-by":"publisher","first-page":"5212","DOI":"10.1158\/0008-5472.CAN-04-0126","article-title":"Class IV semaphorins promote angiogenesis by stimulating Rho-initiated pathways through plexin-B","volume":"64","author":"Basile","year":"2004","journal-title":"Cancer Res."},{"key":"B81","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1158\/2326-6066.CIR-14-0171","article-title":"Antibody blockade of semaphorin 4D promotes immune infiltration into tumor and enhances response to other immunomodulatory therapies","volume":"3","author":"Evans","year":"2015","journal-title":"Cancer Immunol Res."},{"key":"B82","doi-asserted-by":"publisher","first-page":"e1054599","DOI":"10.1080\/2162402X.2015.1054599","article-title":"Immunomodulation of the tumor microenvironment by neutralization of Semaphorin 4D","volume":"4","author":"Evans","year":"2015","journal-title":"Oncoimmunology."},{"key":"B83","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0896-6273(02)00750-X","article-title":"Plexin-B1 directly interacts with PDZ-RhoGEF\/LARG to regulate RhoA and growth cone morphology","volume":"35","author":"Swiercz","year":"2002","journal-title":"Neuron."},{"key":"B84","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1126\/science.1097545","article-title":"The semaphorin 4D receptor plexinB1 is a GTPase activating protein for R-Ras","volume":"305","author":"Oinuma","year":"2004","journal-title":"Science."},{"key":"B85","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/sj.embor.7400737","article-title":"Sema4D\/plexin-B1 activates GSK-3beta through R-Ras GAP activity, inducing growth cone collapse","volume":"7","author":"Ito","year":"2006","journal-title":"EMBO Rep."},{"key":"B86","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/S1471-4906(01)02087-7","article-title":"The CD100-CD72 interaction: a novel mechanism of immune regulation","volume":"22","author":"Kumanogoh","year":"2001","journal-title":"Trends Immunol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S1074-7613(00)00062-5","article-title":"Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: a novel mechanism for regulating B cell signaling","volume":"13","author":"Kumanogoh","year":"2000","journal-title":"Immunity."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.4049\/jimmunol.0903302","article-title":"Roles of Sema4D-plexin-B1 interactions in the central nervous system for pathogenesis of experimental autoimmune encephalomyelitis","volume":"184","author":"Okuno","year":"2010","journal-title":"J Immunol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.nbd.2015.01.002","article-title":"Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease","volume":"76","author":"Southwell","year":"2015","journal-title":"Neurobiol Dis."},{"key":"B90","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0092-8674(01)00237-9","article-title":"The TNF and TNF receptor superfamilies: integrating mammalian biology","volume":"104","author":"Locksley","year":"2001","journal-title":"Cell."},{"key":"B91","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/0092-8674(95)90192-2","article-title":"The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor","volume":"83","author":"Grell","year":"1995","journal-title":"Cell."},{"key":"B92","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0898-6568(01)00262-5","article-title":"TNF receptor subtype signalling: differences and cellular consequences","volume":"14","author":"MacEwan","year":"2002","journal-title":"Cell Signal."},{"key":"B93","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nri1184","article-title":"Signalling pathways of the TNF superfamily: a double-edged sword","volume":"3","author":"Aggarwal","year":"2003","journal-title":"Nat Rev Immunol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.3390\/ijms19051442","article-title":"A new venue of TNF targeting","volume":"19","author":"Steeland","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B95","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.cytogfr.2014.07.016","article-title":"TNF and TNFreceptors: from mediators of cell death and inflammation to therapeutic giants - past, present and future","volume":"25","author":"Sedger","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"B96","doi-asserted-by":"publisher","first-page":"a008656","DOI":"10.1101\/cshperspect.a008656","article-title":"Caspase functions in cell death and disease","volume":"5","author":"McIlwain","year":"2013","journal-title":"Cold Spring Harb Perspect Biol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.nbd.2015.08.011","article-title":"Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers","volume":"83","author":"Politis","year":"2015","journal-title":"Neurobiol Dis."},{"key":"B98","doi-asserted-by":"publisher","first-page":"4328","DOI":"10.1093\/hmg\/ddu151","article-title":"Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease","volume":"23","author":"Hsiao","year":"2014","journal-title":"Hum Mol Genet."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1126\/science.1081297","article-title":"Inactivation of TNF signaling by rationally designed dominant-negative TNF variants","volume":"301","author":"Steed","year":"2003","journal-title":"Science."},{"key":"B100","doi-asserted-by":"publisher","first-page":"7202","DOI":"10.1038\/s41598-019-43627-3","article-title":"Inhibition of tumour necrosis factor alpha in the R6\/2 mouse model of Huntington's disease by etanercept treatment","volume":"9","author":"Pido-Lopez","year":"2019","journal-title":"Sci Rep."},{"key":"B101","doi-asserted-by":"publisher","first-page":"378","DOI":"10.2174\/156720507781788873","article-title":"TNFalpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets","volume":"4","author":"Tweedie","year":"2007","journal-title":"Curr Alzheimer Res."},{"key":"B102","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1742-2094-5-45","article-title":"TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease","volume":"5","author":"McCoy","year":"2008","journal-title":"J Neuroinflammation."},{"key":"B103","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S1474-4422(04)00937-8","article-title":"The promise of minocycline in neurology","volume":"3","author":"Yong","year":"2004","journal-title":"Lancet Neurol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/77528","article-title":"Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease","volume":"6","author":"Chen","year":"2000","journal-title":"Nat Med."},{"key":"B105","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.bbadis.2005.11.002","article-title":"Combination therapy using minocycline and coenzyme Q10 in R6\/2 transgenic Huntington's disease mice","volume":"1762","author":"Stack","year":"2006","journal-title":"Biochim Biophys Acta."},{"key":"B106","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/ana.10614","article-title":"Minocycline and doxycycline are not beneficial in a model of Huntington's disease","volume":"54","author":"Smith","year":"2003","journal-title":"Ann Neurol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.nbd.2004.09.017","article-title":"Minocycline in phenotypic models of Huntington's disease","volume":"18","author":"Bantubungi","year":"2005","journal-title":"Neurobiol Dis."},{"key":"B108","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1111\/j.0953-816X.2004.03372.x","article-title":"Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease","volume":"19","author":"Diguet","year":"2004","journal-title":"Eur J Neurosci."},{"key":"B109","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1385\/NMM:9:1:47","article-title":"Lack of minocycline efficiency in genetic models of Huntington's disease","volume":"9","author":"Mievis","year":"2007","journal-title":"Neuromolecular Med."},{"key":"B110","doi-asserted-by":"publisher","first-page":"6186","DOI":"10.1093\/hmg\/ddv335","article-title":"Transcriptional dysregulation of inflammatory\/immune pathways after active vaccination against Huntington's disease","volume":"24","author":"Ramsingh","year":"2015","journal-title":"Hum Mol Genet."},{"key":"B111","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S1525-0016(03)00063-7","article-title":"DNA vaccination against mutant huntingtin ameliorates the HDR6\/2 diabetic phenotype","volume":"7","author":"Miller","year":"2003","journal-title":"Mol Ther."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1080\/19420862.2015.1076601","article-title":"Specific in vivo knockdown of protein function by intrabodies","volume":"7","author":"Marschall","year":"2015","journal-title":"MAbs."},{"key":"B113","doi-asserted-by":"publisher","first-page":"e29199","DOI":"10.1371\/journal.pone.0029199","article-title":"Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments","volume":"6","author":"Butler","year":"2011","journal-title":"PLoS ONE."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1097\/NEN.0b013e3181f530ec","article-title":"Early or late-stage anti-Nterminal huntingtin intrabody gene therapy reduces pathological features in B6.HDR6\/1 mice","volume":"69","author":"Snyder-Keller","year":"2010","journal-title":"J Neuropathol Exp Neurol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"9013","DOI":"10.1523\/JNEUROSCI.2747-08.2008","article-title":"Intrabodies binding the prolinerich domains of mutant huntingtin increase its turnover and reduce neurotoxicity","volume":"28","author":"Southwell","year":"2008","journal-title":"J Neurosci."},{"key":"B116","doi-asserted-by":"publisher","first-page":"13589","DOI":"10.1523\/JNEUROSCI.4286-09.2009","article-title":"Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease","volume":"29","author":"Southwell","year":"2009","journal-title":"J Neurosci."},{"key":"B117","doi-asserted-by":"publisher","first-page":"7120753","DOI":"10.1155\/2016\/7120753","article-title":"An intrabody drug (rAAV6-INT41) reduces the binding of N-Terminal Huntingtin fragment(s) to DNA to basal levels in PC12 cells and Delays cognitive loss in the R6\/2 animal model","volume":"2016","author":"Amaro","year":"2016","journal-title":"J Neurodegener Dis."},{"key":"B118","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1093\/hmg\/ddn175","article-title":"Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease","volume":"17","author":"Wang","year":"2008","journal-title":"Hum Mol Genet."},{"key":"B119","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.imbio.2015.10.002","article-title":"A critical role for alpha-synuclein in development and function of T lymphocytes","volume":"221","author":"Shameli","year":"2016","journal-title":"Immunobiology."},{"key":"B120","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nature22815","article-title":"T cells from patients with Parkinson's disease recognize alpha-synuclein peptides","volume":"546","author":"Sulzer","year":"2017","journal-title":"Nature."},{"key":"B121","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1002\/acn3.580","article-title":"Immunosuppressants and risk of Parkinson disease","volume":"5","author":"Racette","year":"2018","journal-title":"Ann Clin Transl Neurol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00401-014-1256-4","article-title":"Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials","volume":"127","author":"Mandler","year":"2014","journal-title":"Acta Neuropathol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.neulet.2013.12.028","article-title":"Immunogenicity of epitope vaccines targeting different B cell antigenic determinants of human alpha-synuclein: feasibility study","volume":"560","author":"Ghochikyan","year":"2014","journal-title":"Neurosci Lett."},{"key":"B124","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1084\/jem.20170335","article-title":"Dendritic cell and antigen dispersal landscapes regulate T cell immunity","volume":"214","author":"Gerner","year":"2017","journal-title":"J Exp Med."},{"key":"B125","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1080\/21645515.2015.1012033","article-title":"Evaluation of an alpha synuclein sensitized dendritic cell based vaccine in a transgenic mouse model of Parkinson disease","volume":"11","author":"Ugen","year":"2015","journal-title":"Hum Vaccin Immunother."},{"key":"B126","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13024-015-0008-9","article-title":"Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy","volume":"10","author":"Mandler","year":"2015","journal-title":"Mol Neurodegener."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.2353\/ajpath.2007.061232","article-title":"Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation","volume":"170","author":"Dufty","year":"2007","journal-title":"Am J Pathol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1073\/pnas.0406976102","article-title":"Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations","volume":"102","author":"Li","year":"2005","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B129","doi-asserted-by":"publisher","first-page":"e19338","DOI":"10.1371\/journal.pone.0019338","article-title":"Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease","volume":"6","author":"Masliah","year":"2011","journal-title":"PLoS ONE."},{"key":"B130","doi-asserted-by":"publisher","first-page":"13454","DOI":"10.1523\/JNEUROSCI.1292-12.2012","article-title":"Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission","volume":"32","author":"Bae","year":"2012","journal-title":"J Neurosci."},{"key":"B131","doi-asserted-by":"publisher","first-page":"9441","DOI":"10.1523\/JNEUROSCI.5314-13.2014","article-title":"Reducing C-terminal-truncated alphasynuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models","volume":"34","author":"Games","year":"2014","journal-title":"J Neurosci."},{"key":"B132","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.celrep.2014.05.033","article-title":"Alpha-synuclein immunotherapy blocks uptake and templated propagation of misfolded alphasynuclein and neurodegeneration","volume":"7","author":"Tran","year":"2014","journal-title":"Cell Rep."},{"key":"B133","doi-asserted-by":"publisher","first-page":"e0116841","DOI":"10.1371\/journal.pone.0116841","article-title":"Anti-human alpha-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-alpha-synuclein rat model of Parkinson's disease","volume":"10","author":"Shahaduzzaman","year":"2015","journal-title":"PLoS ONE."},{"key":"B134","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.nbd.2014.05.009","article-title":"Immunotherapy targeting alphasynuclein protofibrils reduced pathology in (Thy-1)h[A30P] alpha-synuclein mice","volume":"69","author":"Lindstr\u00f6m","year":"2014","journal-title":"Neurobiol Dis."},{"key":"B135","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3389\/fnins.2018.00452","article-title":"Region-specific effects of immunotherapy with antibodies targeting alpha-synuclein in a transgenic model of synucleinopathy","volume":"12","author":"Kallab","year":"2018","journal-title":"Front Neurosci."},{"key":"B136","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.nbd.2018.10.016","article-title":"Development of an aggregateselective, human-derived alpha-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models","volume":"124","author":"Weihofen","year":"2019","journal-title":"Neurobiol Dis."},{"key":"B137","doi-asserted-by":"publisher","first-page":"104582","DOI":"10.1016\/j.nbd.2019.104582","article-title":"Preclinical development of a high affinity alpha-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular alpha-synuclein and attenuate alpha-synuclein spreading in vivo","volume":"132","author":"Schofield","year":"2019","journal-title":"Neurobiol Dis."},{"key":"B138","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.coph.2018.07.008","article-title":"Recent advances in combinatorial drug screening and synergy scoring","volume":"42","author":"Pemovska","year":"2018","journal-title":"Curr Opin Pharmacol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.cels.2019.01.003","article-title":"Quantifying drug combination synergy along potency and efficacy axes","volume":"8","author":"Meyer","year":"2019","journal-title":"Cell Syst."},{"key":"B140","doi-asserted-by":"publisher","first-page":"e00747","DOI":"10.7554\/eLife.00747","article-title":"Evolutionary dynamics of cancer in response to targeted combination therapy","volume":"2","author":"Bozic","year":"2013","journal-title":"Elife."},{"key":"B141","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1158\/0008-5472.CAN-17-1201","article-title":"Combination therapy and the evolution of resistance: the theoretical merits of synergism and antagonism in cancer","volume":"78","author":"Saputra","year":"2018","journal-title":"Cancer Res."},{"key":"B142","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Bayat Mokhtari","year":"2017","journal-title":"Oncotarget."},{"key":"B143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.06.028","article-title":"Rationale for anti-GITR cancer immunotherapy","volume":"67","author":"Knee","year":"2016","journal-title":"Eur J Cancer."},{"key":"B144","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1200\/JCO.2017.35.15_suppl.104","article-title":"Preliminary results of a phase I\/IIa study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor-related gene [GITR] agonist), alone and in combination with nivolumab in pts with advanced solid tumors","volume":"35","author":"Siu","year":"2017","journal-title":"J Clin Oncol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1479-5876-12-36","article-title":"Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs","volume":"12","author":"Lu","year":"2014","journal-title":"J Transl Med."},{"key":"B146","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature."},{"key":"B147","doi-asserted-by":"publisher","first-page":"eaat7061","DOI":"10.1126\/sciimmunol.aat7061","article-title":"Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8(+) t cell dysfunction and maintain memory phenotype","volume":"3","author":"Wang","year":"2018","journal-title":"Sci Immunol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"e0184040","DOI":"10.1371\/journal.pone.0184040","article-title":"Proteasome impairment by alpha-synuclein","volume":"12","author":"Zondler","year":"2017","journal-title":"PLoS ONE."},{"key":"B149","doi-asserted-by":"publisher","first-page":"281","DOI":"10.4161\/auto.8.2.18938","article-title":"Alpha-synuclein's degradation in vivo: opening a new (cranial) window on the roles of degradation pathways in Parkinson disease","volume":"8","author":"Ebrahimi-Fakhari","year":"2012","journal-title":"Autophagy."},{"key":"B150","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/mt.2012.66","article-title":"Lentivirus mediated delivery of neurosin promotes clearance of wild-type alphasynuclein and reduces the pathology in an alphasynuclein model of LBD","volume":"21","author":"Spencer","year":"2013","journal-title":"Mol Ther."},{"key":"B151","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1515\/revneuro-2017-0040","article-title":"Neurotrophic factors hold promise for the future of Parkinson's disease treatment: is there a light at the end of the tunnel?","volume":"29","author":"Nasrolahi","year":"2018","journal-title":"Rev Neurosci."},{"key":"B152","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.neulet.2011.03.088","article-title":"Vascular endothelial growth factor-B is neuroprotective in an in vivo rat model of Parkinson's disease","volume":"496","author":"Falk","year":"2011","journal-title":"Neurosci Lett."},{"key":"B153","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.2147\/IJN.S61940","article-title":"Increased antiParkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease","volume":"9","author":"Herr\u00e1n","year":"2014","journal-title":"Int J Nanomedicine."},{"key":"B154","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40478-016-0409-1","article-title":"Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy","volume":"5","author":"Valera","year":"2017","journal-title":"Acta Neuropathol Commun."},{"key":"B155","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41531-016-0001-1","article-title":"Combined immunotherapy with \u201canti-insulin resistance\u201d therapy as a novel therapeutic strategy against neurodegenerative diseases","volume":"3","author":"Takamatsu","year":"2017","journal-title":"NPJ Parkinsons Dis."},{"key":"B156","doi-asserted-by":"publisher","first-page":"9299","DOI":"10.1074\/jbc.M111.313080","article-title":"Insulin promotes neuronal survival via the alternatively spliced protein kinase CdeltaII isoform","volume":"287","author":"Apostolatos","year":"2012","journal-title":"J Biol Chem."},{"key":"B157","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.neurobiolaging.2014.11.018","article-title":"Modulation of insulin signaling rescues BDNF transport defects independent of tau in amyloid-beta oligomer-treated hippocampal neurons","volume":"36","author":"Takach","year":"2015","journal-title":"Neurobiol Aging."},{"key":"B158","doi-asserted-by":"publisher","first-page":"8916","DOI":"10.1007\/s12035-018-0985-0","article-title":"Evidence for compromised insulin signaling and neuronal vulnerability in experimental model of sporadic alzheimer's disease","volume":"55","author":"Gupta","year":"2018","journal-title":"Mol Neurobiol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00337\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T06:19:49Z","timestamp":1582611589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00337\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,25]]},"references-count":158,"alternative-id":["10.3389\/fimmu.2020.00337"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00337","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,25]]},"article-number":"337"}}